Mutations in ABL kinase domain are associated with inferior progression-free survival

References

• Druker BJ, Guilhot F, O'Brien SG, et al; IRIS Investigators. Five year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408–2417.
   PubMed Web of Science ®Google Scholar
• Goldman JM. How I treat CML chronic myeloid leukemia in the imatinib era. Blood 2007;110:2828–2837.
   PubMed Web of Science ®Google Scholar
• Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96:3343–3356.
   PubMed Web of Science ®Google Scholar
• Savage DG, Antman KH. Imatinib mesylate – a new oral targeted therapy. N Engl J Med 2002;346:683–693.
   PubMed Web of Science ®Google Scholar
• O'Brien SG, Guilhot F, Larson RA, et al; IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994–1004.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Sawyers CL, Kantarjian H, et al Activity of a specific inhibitor of BCR-ABL tyrosine kinase in the blast crisis of chronic myelogenous leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038–1042.
   PubMed Web of Science ®Google Scholar
• Von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutation in relation to clinical resistance of Philadelphia-chromosome positive leukemia to STI571: a prospective study. Lancet 2002;359:487–491.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H, Jones D, et al Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006;20:1767–1773.
   PubMed Web of Science ®Google Scholar
• Gorre ME, Mohammed M, Ellwood K, et al Clinical resistance to STI571cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876–880.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Kreil S, Corbin AS, et al Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002;16:2190–2196.
   PubMed Web of Science ®Google Scholar
• Branford S, Rudzki Z, Walsh S, et al High frequency of point mutation clustered within adenosine triphosphate binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002;99:3472–3475.
   PubMed Web of Science ®Google Scholar
• Branford S, Rudzki Z, Walsh S, et al Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance and mutations in ATP phosphate-binding loop (p-loop) are associated with a poor prognosis. Blood 2003;102:276–283.
   PubMed Web of Science ®Google Scholar
• O'Hare TA, Eide C, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007;110:2242–2249.
   PubMed Web of Science ®Google Scholar
• Kumar L. Chronic myelogenous leukemia (CML): an update. Nat Med J India 2006;19:255–263.
   PubMed Web of Science ®Google Scholar
• Kuila N, Sahoo DP, Kumari M, et al EVI1 and AME. Prevalence of the secondary mutations in chronic and accelerated phases of chronic myeloid leukemia patients from eastern India. Leuk Res 2009;33:594–596.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Sagio G, Goldman J, et al Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809–1820.
   PubMed Web of Science ®Google Scholar
• Gabert J, Beillard E, van der Velden VJH, et al Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program. Leukemia 2003;17:2318–2357.
   PubMed Web of Science ®Google Scholar
• Shah NP, Nicoll JM, Nagar B, et al Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117–125.
   PubMed Web of Science ®Google Scholar
• Soverini S, Martinelli G, Rosti G, Bassi S, Ambile M, Poerio A. ABL mutations in late chronic phase chronic myeloid leukemia with up front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival :a study by GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005;23:4100–4109.
   PubMed Web of Science ®Google Scholar
• Nicolini FE, Corm S, Lê QH, et al Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia 2006;6:1061–1066.
   Web of Science ®Google Scholar
• Khorashad JS, de Lavallade H, Apperley JF, et al Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol 2008;26:4806–4813.
   PubMed Web of Science ®Google Scholar
• Singh N, Kumar L, Meena R, Velpandian T. Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders. Eur J Clin Pharmacol 2009;65:545–549.
   PubMed Web of Science ®Google Scholar
• Hamdan MY, Sanders L, Oliveria S, et al Discontinuation and dose modification of imatinib in clinical practice. J Clin Oncol 2007;25(18S): Abstract 7045.
   Google Scholar
• Campbell LJ, Patsouris C, Rayeroux KC, Somana K, Januszewicz EH, Szer J. BCR-ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration. Cancer Genet Cytogenet 2002;139:30–33.
   PubMed Web of Science ®Google Scholar
• Morel F, Bris MJ, Herry A, et al Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib. Eur J Haematol 2003;70:235–239.
   PubMed Web of Science ®Google Scholar
• Mahon FX, Deininger MW, Schultheis B, et al Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI-571: diverse mechanism of resistance. Blood 2000;96:1070–1079.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Kantarjian HM, Baccarani M, et al Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007;109:2303–2309.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Giles F, Bhalla KN, et al Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study. Blood 2008;112: 3238 (abstract).
   Web of Science ®Google Scholar
• Baccarani M, Cortes J, Pane F, et al Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041–6051.
   PubMed Web of Science ®Google Scholar